

Grace Lu-Yao, PhD, MPH

Associate Director of Population Science at the Sidney
Kimmel Cancer Center at Thomas Jefferson University

Education

| | |
|---|-------------|
| Taipei Medical College | 1981- 1984 |
| BS, State University of New York at Stonybrook (Biochemistry) | 1984 - 1986 |
| MPH, Yale University (Public Health) | 1986 - 1988 |
| PhD, Yale University (Epidemiology) | 1988 - 1990 |
| Jefferson Leadership Academy | 2018 - 2019 |

Professional Appointments

| | |
|--|--------------|
| Assistant Professor, Community and Family Medicine, Dartmouth | 1990-1994 |
| Staff Researcher, Office of Research in Centers for Medicare and Medicaid Services | 1995-1996 |
| Director, Health Stat | 1997-2003 |
| Associate Professor, Environmental and Occupational Medicine, UMDNJ | 2004-2008 |
| Associate Professor, Medicine, Rutgers University | 2008-2010 |
| Professor, Medicine & Epidemiology, Rutgers University | 2010-2016 |
| Visiting Professor, Harvard University | 2015-2016 |
| Professor, Sidney Kimmel Medical College, TJU Medical Oncology | 2016-Present |
| Associate Director, Population Science, Sidney Kimmel Cancer Center at Jefferson | 2016-Present |
| Board Member, International Network for Cancer Treatment and Research | 2018-Present |

Honors and Awards

| | |
|---|----------------|
| Marquis Who's Who | 2012 - present |
| Distinguished Visiting Professor, Uniformed Services/University of Health Sciences | 2016 |
| International Society of Geriatric Oncology 2018 Nursing and Allied Health Investigator Award | 2018 |

Selected Peer Reviewed Publications

1. **Lu-Yao G**, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy for prostate cancer: time trends, geographic variations, and outcomes. *JAMA* 1993; 269:2633-2636. PMID: 8487445
2. **Lu-Yao G**, Keller RB, Littenberg B, Wennberg JE. Outcomes of alternative operative treatment of elderly patients with displaced femoral neck fractures. *J Bone Joint Surg [Am]* 1994; 76A:15-25.
3. **Lu-Yao G**, Greenberg R. Geographic variation in rates of prostate cancer and radical prostatectomy in the United States. *Lancet* 1994; 343:251-54.
4. **Lu-Yao G**, Potosky A, Albertsen P, Wasson J, Wennberg JE. Follow-up cancer treatments after radical prostatectomy among patients with prostate cancer. *J Natl Cancer Inst* 1996; 88:166-173. PMID: 8632490
5. **Lu-Yao G**, Yao S. Outcomes of treatments for clinically localized prostate cancer. *Lancet* 1997; 349:906-910
6. **Lu-Yao G**, Albertsen PC, Stanford JL, Stukel TA, Walker-Cornery ES, Barry MJ. A natural experiment examining the impact of aggressive screening and treatment on prostate cancer mortality. *British Medical Journal* 2002; 325:740-43. PMID: PMC128373
7. **Lu-Yao G**, Stukel TA, Yao SL. Prostate-specific antigen screening in elderly men. *J Natl Cancer Inst* 2003; 95:1792-7
8. **Lu-Yao G**, Moore DF, Shih W, Lin Y, DiPaola RS, Albertsen P, Yao SL. Survival following primary androgen deprivation therapy among men with localized prostate cancer. *JAMA* 2008; 300:173-181. PMID: 18612114.PMCID: PMC2645653
9. **Lu-Yao G**, Albertsen P, Moore DF...Yao SL. Outcomes of localized prostate cancer following conservative management. *JAMA* 2009; 302(11):1202-1209. PMID: 19755699. PMCID: PMC2822438
10. Shao YU, Demissie K, Shih W, Mehta A, Stein M, Roberts C, DiPaola RS, **Lu-Yao G**. Contemporary risk profile of prostate cancer in the United States. *JNCI* 2009;101:1280-1283. PMID: 19713548.PMCID: PMC2744729
11. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, **Lu-Yao G**. The impact of co-morbidity on survival among men with localized prostate cancer. *J Clin Oncol* 2011 Feb 28 (e-print). PMID: PMC3084001
12. Kim S, Moore D, Shih W, Lin Y, Shen S, Li H, Dolan M, Shao YJ, **Lu-Yao G**. Late gastrointestinal toxicities following radiation therapy for prostate cancer. *Eur Urol* 2011; 60(5):908-916. PMID: 21684064. PMCID: PMC3185133.

13. **Lu-Yao G**, Albertsen PC, Li H, Moore DF, Shih W, Lin Y, DiPaola R, Yao SL. Does Primary Androgen Deprivation Therapy Delay the Receipt for Secondary Cancer Therapy for Localized Prostate Cancer? *Eur Urol* 2012; 62(6):966-72. PMID: 22608160.PMCID: PMC3472155.
14. Shao, Y-H, Kim, S, Moore, DF, Shih, W, Lin, Y, Stein, M, Kim, IY, **Lu-Yao, G**. Cancer-Specific Survival after Metastasis Following Primary Radical Prostatectomy versus Radiation Therapy in Prostate Cancer Patients: Results of a population based, propensity score matched analysis. *Eur Urol* 2014 Apr;65(4):693-700. PMID: 23759328 PMCID: PMC3825778
15. **Lu-Yao G**, Albertsen P, Moore D, Shih W, Lin Y, DiPaola R, Yao S. Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer. *JAMA Intern Med.* 2014; 174(9):1460-1467. PMID: 25023796.PMCID:PMC5499229
16. **Lu-Yao G**, Albertsen PC, Moore D, Lin Y, DiPaola RS, Yao SL. 15-year outcomes following conservative management among patients with screen-detected localized prostate cancer. *Eur Urol* 2015;68(5) 805-11. PMID: 25800944. PMCID PMC4575827
17. He J, Albertsen P, Moore D, Rotter D, Demissie K, **Lu-Yao G** Validation of a Contemporary Five-Tiered Gleason Grade Grouping Using Population-based Data. *Eur Urol* 2017 May;71(5):760-763. doi: <http://dx.doi.org/10.1016/j.eururo.2016.11.031>. PMID: 27939073
18. Giri VN, Knudsen KE, Kelly WK, Abida W, ...**Lu-Yao G**,... Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. *J Clin Oncol* 2018 Feb 1; 36(4):414-424. doi: 10.1200/JCO.2017.74.1173.PMID: 29236593. PMCID : PMC6075860
19. Jang T, Patel N, Faiena I, ...**Lu-Yao G**. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer.” *Cancer* 2018 Oct 15;124(20):4010-4022. doi: 10.1002/cncr.31726. PMID: 30252932 PMCID: PMC6234085
20. **Lu-Yao, G**, Nikita, N, Keith, et al. Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities. *Eur Urol*, 2019. 77(2) p.158-166.
21. Xiang-Lin Tan, Jian-Yu E, ...**Lu-Yao G**. Individual and Joint Effects of Metformin and Statins on Mortality among Patients with High-Risk Prostate Cancer. *Cancer Med J*, 2020. (00) p. 1-11. DOI: 10.1002/cam4.2862
22. **Lu-Yao G**, Nightingale G, Nikita N,... Kelly WK; Relationship between Polypharmacy Status and Healthcare Utilization in Geriatric Oncology Patients Undergoing Intravenous Chemotherapy. *J Ger Onc* 2020. DOI: 10.1016/j.jgo.2020.03.001

Selected media coverage

1. New York Times: Wait-and-See Policy Backed for Prostate <http://www.nytimes.com/1993/05/26/health/wait-and-see-policy-backed-for-prostate.html>
2. U.S. News & World Report: August 13, 2019: Hormone Therapy for Prostate Cancer Might Harm the Heart: Study <https://www.usnews.com/news/health-news/articles/2019-08-13/hormone-therapy-for-prostate-cancer-might-harm-the-heart-study>
3. US News & World Report: February 13, 2020: Cholesterol Drugs Might Help Curb 'High-Risk' Prostate Cancers, <https://www.usnews.com/news/health-news/articles/2020-02-14/cholesterol-drugs-might-help-curb-high-risk-prostate-cancers>

Selected Peer-Reviewed Support: Principal Investigator

- | | |
|-------------|--|
| 09/01-03/06 | R01HS10278. AHRQ, “Prostate Cancer Screening and Mortality: Seattle vs. Connecticut” |
| 08/06-07/15 | R01CA116399. NIH/NCI, “Evaluation of Palliative Prostate Cancer Care among Elderly Men” |
| 09/07-09/09 | R03 CA132127. NIH/NCI, “Metabolic syndrome and cancer mortality: mechanisms and potential intervention” |
| 09/09-09/12 | Challenge grant R01 RC1CA145722. NIH/NCI, “Evaluate long-term prognosis of localized prostate cancer following initial radiation therapy” |
| 09/18-08/21 | P20CA233255 project 2: Precision of Aggressive Prostate Cancer in African American Men Site PI, P20CA233255 Director of the Development Research Program |

